Agenus to use Selexis’ technology to produce therapeutic proteins

This article was originally published here

Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins. Selexis licensing and business development vice

The post Agenus to use Selexis’ technology to produce therapeutic proteins appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply